2024.06.06

ROCKVILLE, Md. , June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ: IMAB ) (the "Company"), a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment

2024.05.22

ROCKVILLE, Md. , May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB ), a U.S. -based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the

2024.04.30

ROCKVILLE, Md. , April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB ), a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has

2024.04.05

ROCKVILLE, Md. , April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB ), a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at

2024.04.02

ROCKVILLE, Md. , April 2, 2024 /PRNewswire/ -- I-Mab (the " Company ") (NASDAQ: IMAB ) a U.S. -based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that

2024.03.14

Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inhibitors

2024.02.07

Agreement marks an important milestone to advance the Company's intent to become a U.S. -based biotech  Agreement provides for a strategic focus in advancing I-Mab's potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reducing